Clinical Trials Logo

Clinical Trial Summary

The purposes of this study are to determine if MEDI8852 administered with standard of care (oseltamivir) will reduce the time to normalization of respiratory function for adults who are hospitalized with influenza caused by Type A strains and to determine if MEDI8852 has an acceptable safety profile in adults who are hospitalized with influenza caused by Type A strains.


Clinical Trial Description

The MEDI8852 phase 2b study will evaluate the efficacy and safety of a single intravenous (IV) dose of MEDI8852 or placebo administered in conjunction with oseltamivir in adult subjects who are hospitalized with influenza caused by Type A strains. Approximately 450 subjects will be enrolled at study centers in North America, Europe, and other regions. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03028909
Study type Interventional
Source MedImmune LLC
Contact
Status Withdrawn
Phase Phase 2
Start date July 24, 2017
Completion date July 26, 2019